Boston Scientific (BSX) is back in focus after confirming a cyberattack that is disrupting global IT systems and limiting its ability to process and ship customer orders, creating fresh operational uncertainty for investors.

The cyberattack disclosure comes after a difficult stretch for Boston Scientific investors, with the stock falling 3.11% on the day of the news and 5.47% over the past week. This extended a year-to-date share price decline of 50.72% and a 1-year total shareholder return loss of 55.87%, despite a small 1.32% 30-day share price gain that suggests fading rather than building momentum.

Scan beyond Boston Scientific and see how other medical and healthcare stocks with resilient fundamentals are trading right now with our hand picked list of solid balance sheet and fundamentals (50 results).

After a 1-year total return loss of 55.87% and fresh pressure from the cyberattack, Boston Scientific now sits at a very different price than it did a year ago. Does that justify buying today, or waiting for a cleaner entry once the dust settles on valuation?

Most Popular Narrative: 25.6% Undervalued

Based on the most widely followed narrative, Boston Scientific’s fair value of $62.69 sits well above the last close at $46.67, which puts the recent cyberattack into a sharper valuation context.

Investment in proprietary, high-margin technologies (e.g., next-gen mapping, advanced diagnostic tools, differentiated urology/neuromodulation pipelines) combined with successful integration of recent acquisitions (Axonics, SoniVie, Intera, Silk Road) expands Boston Scientific's addressable market and is likely to drive margin expansion as product mix improves.

Enhanced scale and operational efficiency through supply chain initiatives, digitalization, and manufacturing automation, together with robust cash flow, positions Boston Scientific to expand operating margins and generate sustainable earnings growth over the long term.

Want to see what sits behind that projected margin lift and future earnings base. The narrative leans heavily on steady top line growth, disciplined profitability and a valuation multiple that assumes investors stay comfortable funding that trajectory.

Result: Fair Value of $62.69 (UNDERVALUED)

However, Boston Scientific still faces real pressure from tariffs and U.S. reimbursement changes that could squeeze margins and weaken the optimistic growth thesis.

Next Steps

Given the mix of concerns and optimism around Boston Scientific right now, it makes sense to check the data yourself and move quickly to form a balanced view. To see both sides of the story in one place, start with the 4 key rewards and 1 important warning sign.

Looking for more investment ideas beyond Boston Scientific?

If you stop with Boston Scientific, you could miss other opportunities that fit your style. Use the screener to quickly surface ideas that match your priorities.

• Target resilience in tougher markets by focusing on companies with stronger finances using the 76 resilient stocks with low risk scores.
• Hunt for quality at a discount by filtering for stocks that combine strong fundamentals with attractive pricing through the 46 high quality undervalued stocks.
• Spot potential standouts early by scanning fundamentally solid companies that fewer investors are watching via the 20 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.